Capdevila J et al. Lenvatinib in patients with advanced grade 1/2 pancreatic and gastrointestinal neuroendocrine tumors: Results of the phase II TALENT trial (GETNE1509). J Clin Oncol 2021;39(20):2304-12. Abstract
Delpassand ES et al. Targeted alpha-emitter therapy with 212Pb-DOTAMTATE for the treatment of metastatic SSTR-expressing neuroendocrine tumors: First-in-humans dose-escalation clinical trial. J Nucl Med 2022;63(9):1326-33. Abstract
El-Rayes BF et al. Safety, pharmacodynamic, and antitumor activity of tidutamab, an SSTR2 x CD3 bispecific antibody, in subjects with advanced neuroendocrine tumors. NANETS 2021;Abstract 109.
Garcia-Carbonero R et al. A phase II/III randomized double-blind study of octreotide acetate LAR with axitinib versus octreotide acetate LAR with placebo in patients with advanced G1-G2 NETs of non-pancreatic origin (AXINET trial-GETNE-1107). ASCO 2021;Abstract 360.
Halperin DM et al. The safety and efficacy of PEN-221 somatostatin analog (SSA)-DM1 conjugate in patients (pts) with advanced GI mid-gut neuroendocrine tumor (NET): Phase 2 results. ASCO 2021;Abstract 4110.
Jonasch E et al. Belzutifan for renal cell carcinoma in von Hippel-Lindau Disease. N Engl J Med 2021;385(22):2036-46. Abstract
Kunz PL et al. A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: Final analysis of efficacy and evaluation of MGMT (ECOG-ACRIN E2211). ASCO 2022;Abstract 4004.
Pavel et al. Efficacy and safety of high-dose lanreotide autogel in patients with progressive pancreatic or midgut neuroendocrine tumours: CLARINET FORTE phase 2 study result. European Journal of Cancer 2021;157:403-14. Abstract
Rindi G et al. Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms. Endocrine Pathology 2022;33(1):115-54. Abstract